The GLP-1 Catalyst: Transforming Healthcare Markets

The advent of GLP-1 receptor agonists is more than just a significant milestone in diabetes and obesity treatment; it presents a real opportunity for systemic change in disease prevention and management as well as in overall health economics. Real Chemistry recently partnered with STAT to bring together a panel of experts for a deeper look at what this will mean for the healthcare industry.

Featuring insights from Guy D’Andrea, Executive Director of Catalyst for Payment Reform; Gary Foster, Ph.D., Chief Scientific Officer of WeightWatchers; Susan Nemetz, Founder and CEO of Corval and The Nemetz Group; Courtney Younglove, M.D., Founder and Medical Director of Heartland Weight Loss, Founder of WellMi and Chief Medical Officer at Journeys Metabolic; and moderated by our own Rita Glaze-Rowe, President of Transformative Healthcare Markets, the panel tackled questions like:

• The first GLP-1 was approved by the FDA almost 20 years ago – why is this conversation so important and relevant today?

• How should the healthcare industry and adjacent sectors be thinking about patient care and engagement in this rapidly evolving era of GLP-1 based obesity treatment?

• What issues are payers considering right now, and what will the world look like when GLP-1s become available to the nearly 70% of the U.S. population who are potential candidates?

• How do companies need to be thinking about scale as products are being commercialized, and are those aspirations viable in the next 5-10 years?

• Where does the industry need to focus over the next 6 months, and how will this help us bridge to the future?

While we’re still in the early days, there is no denying that the obesity market and GLP-1s are transforming the healthcare landscape with the potential to reset how healthcare and wellness companies engage with consumers, physicians and other stakeholders. That’s why Real Chemistry launched IRIS – the only insights as a service platform designed to help leaders understand the forces driving the healthcare ecosystem’s most disruptive markets, providing the insights and direction they need to anticipate, respond and positively impact patient care.

See below for a recording of the panel discussion to learn more about the short- and long-term impacts of GLP-1s on the healthcare and wellness industries. Are you ready?

Want more insights on the people, stories and ideas that are changing healthcare into what it should be? Subscribe to our Healthcare Connection newsletter and get transformative ideas delivered to your inbox every month.